153 related articles for article (PubMed ID: 34825857)
1. NLRX1 can counteract innate immune response induced by an external stimulus favoring HBV infection by competitive inhibition of MAVS-RLRs signaling in HepG2-NTCP cells.
Jiao Q; Xu W; Guo X; Liu H; Liao B; Zhu X; Chen C; Yang F; Wu L; Xie C; Peng L
Sci Prog; 2021 Oct; 104(4):368504211058036. PubMed ID: 34825857
[TBL] [Abstract][Full Text] [Related]
2. NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2.
Qin Y; Xue B; Liu C; Wang X; Tian R; Xie Q; Guo M; Li G; Yang D; Zhu H
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956771
[TBL] [Abstract][Full Text] [Related]
3. IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor.
Chen C; Zhu X; Xu W; Yang F; Zhang G; Wu L; Zheng Y; Gao Z; Xie C; Peng L
Antiviral Res; 2017 Nov; 147():11-18. PubMed ID: 28958921
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells.
Zhang J; Liu K; Zhang G; Ling N; Chen M
Virol J; 2022 Feb; 19(1):28. PubMed ID: 35144643
[TBL] [Abstract][Full Text] [Related]
5. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein.
Wei C; Ni C; Song T; Liu Y; Yang X; Zheng Z; Jia Y; Yuan Y; Guan K; Xu Y; Cheng X; Zhang Y; Yang X; Wang Y; Wen C; Wu Q; Shi W; Zhong H
J Immunol; 2010 Jul; 185(2):1158-68. PubMed ID: 20554965
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
[TBL] [Abstract][Full Text] [Related]
7. ADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response.
Li T; Yang X; Li W; Song J; Li Z; Zhu X; Wu X; Liu Y
Mol Ther; 2021 Mar; 29(3):1335-1348. PubMed ID: 33279720
[TBL] [Abstract][Full Text] [Related]
8. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways.
Allen IC; Moore CB; Schneider M; Lei Y; Davis BK; Scull MA; Gris D; Roney KE; Zimmermann AG; Bowzard JB; Ranjan P; Monroe KM; Pickles RJ; Sambhara S; Ting JP
Immunity; 2011 Jun; 34(6):854-65. PubMed ID: 21703540
[TBL] [Abstract][Full Text] [Related]
9. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.
Suárez-Amarán L; Usai C; Di Scala M; Godoy C; Ni Y; Hommel M; Palomo L; Segura V; Olagüe C; Vales A; Ruiz-Ripa A; Buti M; Salido E; Prieto J; Urban S; Rodríguez-Frias F; Aldabe R; González-Aseguinolaza G
J Hepatol; 2017 Oct; 67(4):669-679. PubMed ID: 28527664
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory siRNA with a uridine bulge leads to potent inhibition of HBV and activation of innate immunity.
Lan T; Wei Z; He Y; Wan S; Liu L; Cheng B; Li R; Chen H; Liu G; Meng Z
Virol J; 2021 Feb; 18(1):37. PubMed ID: 33602251
[TBL] [Abstract][Full Text] [Related]
11. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
Chen X; Qian Y; Yan F; Tu J; Yang X; Xing Y; Chen Z
Eur J Pharmacol; 2013 Dec; 721(1-3):86-95. PubMed ID: 24099962
[TBL] [Abstract][Full Text] [Related]
12. Residues Asn118 and Glu119 of hepatitis B virus X protein are critical for HBx-mediated inhibition of RIG-I-MAVS signaling.
Wang F; Shen F; Wang Y; Li Z; Chen J; Yuan Z
Virology; 2020 Jan; 539():92-103. PubMed ID: 31706164
[TBL] [Abstract][Full Text] [Related]
13. NLRX1 is a regulator of mitochondrial antiviral immunity.
Moore CB; Bergstralh DT; Duncan JA; Lei Y; Morrison TE; Zimmermann AG; Accavitti-Loper MA; Madden VJ; Sun L; Ye Z; Lich JD; Heise MT; Chen Z; Ting JP
Nature; 2008 Jan; 451(7178):573-7. PubMed ID: 18200010
[TBL] [Abstract][Full Text] [Related]
14. [Novel vector preS1-tp fusion protein effectively inhibits hepatitis B virus replication and cccDNA synthesis by mediating hepatitis B virus targeting sequence small interfering RNA].
Zeng YL; Gao F; Zhang C; Wei JF; Ma L; Ding GG; Li W; Shang J; Kang Y
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):126-132. PubMed ID: 33685080
[No Abstract] [Full Text] [Related]
15. Interferon-gamma (IFN-gamma) response to different hepatitis B virus antigens in hepatitis B virus infection.
Paul S; Tabassum S; Islam MN
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):71-7. PubMed ID: 15813485
[TBL] [Abstract][Full Text] [Related]
16. NLRX1 attenuates apoptosis and inflammatory responses in myocardial ischemia by inhibiting MAVS-dependent NLRP3 inflammasome activation.
Li H; Zhang S; Li F; Qin L
Mol Immunol; 2016 Aug; 76():90-7. PubMed ID: 27393910
[TBL] [Abstract][Full Text] [Related]
17. DNA-dependent activator of interferon-regulatory factors inhibits hepatitis B virus replication.
Chen QY; Liu YH; Li JH; Wang ZK; Liu JX; Yuan ZH
World J Gastroenterol; 2012 Jun; 18(22):2850-8. PubMed ID: 22719196
[TBL] [Abstract][Full Text] [Related]
18. Anti-hepatitis B virus activity of lithospermic acid, a polyphenol from Salvia miltiorrhiza, in vitro and in vivo by autophagy regulation.
Zhu S; Wen H; Wang W; Chen Y; Han F; Cai W
J Ethnopharmacol; 2023 Feb; 302(Pt A):115896. PubMed ID: 36334815
[TBL] [Abstract][Full Text] [Related]
19. [Effect of PLSCR1 on the Antiviral Activity of IFN against HBV in HepG2 Cells].
Li Q; Zhang B; Zhang Q; Wang X; Huo Y; Yang J
Bing Du Xue Bao; 2016 Nov; 32(6):747-51. PubMed ID: 30004207
[TBL] [Abstract][Full Text] [Related]
20. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
